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Treatment alternatives for Attention-Deficit/ Hyperactivity Disorder (ADHD) 
L.E. Arnold 
Objective 
To review alternate treatments (Tx) of Attention-Deficit/Hyperactivity Disorder (ADHD)—those 
other than psychoactive medication and behavioral/psychosocial Tx—for the November, 1998 National 
Institute of Health (NIH) Consensus Development Conference on ADHD. 
Method: 
The literature was searched on Medline and Psychlnfo 1963-1998 and investigators known to be 
interested in alternate Tx were contacted for unpublished data. 
Results: 
Twenty-three alternate Tx were identified, ranging in scientific documentation from discrediting 
controlled studies through mere hypotheses to positive controlled double-blind clinical trials. Many of them 
are applicable only to a restricted etiological subgroup. The oligoantigenic or few-foods diet has convincing 
double-blind evidence of efficacy in multiple trials for a properly selected subgroup. Enzyme-potentiated 
desensitization to foods, relaxation/EMG biofeedback, and deleading also have controlled evidence of 
efficacy. Glyconutritional supplementation, iron supplementation, magnesium supplementation, Chinese 
herbals, EEG biofeedback, meditation, mirror feedback, channel-specific perceptual training, and vestibular 
stimulation all have promising prospective pilot data. Single-vitamin megadosage has some intriguing pilot 
trial data. Zinc supplementation is hypothetically supported by systematic case-control data but has no 
systematic clinical trial. Laser acupuncture has promising unpublished pilot data. Essential fatty acid 
supplementation has promising systematic case-control data but clinical trials are equivocal. 
Recommended-Daily-Allowance vitamin supplementation, nonChinese herbals, homeopathic remedies, and 
antifungal therapy have no systematic data in ADHD. Megadose multivitamin combinations are probably 
ineffective for most patients and possibly dangerous. Simple sugar restriction and hypnosis seem ineffective. 
Amino acid supplementation, though mildly effective in the short term, is not effective beyond a few weeks. 
Thyroid Tx is effective in the presence of documented thyroid abnormality, but not otherwise. 
Conclusion 
Some alternate Tx of ADHD are effective or probably effective, but mainly for restricted etiologic 
subgroups. In some cases they are the Tx of choice, and initial evaluation should consider the relevant 
etiologies. A few have failed to prove effective in controlled trials. Most need research to determine whether 
they are effective and/or to define the applicable subgroup. Some of them, though not safer than standard Tx, 
may be preferable for an etiologic subgroup. 
Attention-Deficit/Hyperactivity Disorder (ADHD) has attracted many kinds of proposed 
treatments. The National Institute of Health (NIH) Consensus Development Conference on 
Diagnosis and Treatment of ADHD, held November 16-18, 1998 at Bethesda, MD, required a 
comprehensive review of possible treatments. Alternate treatments (Tx), or treatment alternatives, 
were defined for this purpose as any treatment other than prescription psychoactive drugs or 
standard behavioral/psychosocial treatments, both of which have already been extensively and 
well reviewed in the extant literature, with undoubted efficacy. In contrast to those two more 
general, established treatments, many alternate treatments are etiologically targeted (see Table 1) 
and consequently
Treatment Etiology or mechanism Type of data ESorp Rating* (0-6); 
recommendation
Risks 
Few foods diet Food or additive Controlled trial; ES 0.5-1.5 5; define subgroup Nuisance, expense, nutrition
(Oligoantigenic) sensitivity placebo challenges p .05-.001 (profile; % ADHD)  
Enzyme-potentiate
d 
Food or additive Controlled comparison p.001 4; replication; define Injection 
desensitization sensitivity to placebo injections  subgroup  
Elimination of 
sugar 
Sugar malaise Placebo-controlled p>.1 0; take FH of DM Delay std Tx 
alone  challenges    
Amino acid Precursors of Placebo-controlled ES up to 0.6 0; despite short-lived Eosinophilia, neurotoxicity 
supplementation catecholamines comparisons p.01 effect of little utility  
Essential fatty acid Prostaglandins, Serum level cf. cntrl ES .05 3; trials of n-3 < Upsetting balance 
supplementation Neural membrane plac.-contr. trials .1 >p>.05 in selected subjects  
Glyconutritional Need for glycoconjugates Open trials, SNAP-IV, p .05-.002 3; placebo trials Upsetting balance 
supplementation  blind teachers    
Vitamins Deficiency or idiopathic Placebo-controlled Megadose 0 for mega-combo; Hepatotoxicity, neuropathy 
 need for higher dose trials megavitamin combo no 1 for RDA, specific in megadose 
  combo, not RDA benefit megavit; pilot trials  
Iron supple- Co-factor in making Open trial ES 1.0 3**; controlled trials Hemochromatosis from 
mentation catecholamines supplementation p< .05  excess 
Zinc supple- Co-factor for Comparison Zn level of ES 2.4 2**; controlled trials WBC aplasia from excess 
mentation many enzymes ADHDtocontrl p < .001   
Magnesium Deficiency cf. to controls Open trial with control ES 1.2-1.4 3**; placebo trials Aggression from excess 
supplementation  group p<.05   
Chinese herbals Clinical exper. Open trials, one with 
MPH control 
p< .05; no 
diff. MPH 
3; placebo trials Delay of other Tx 
Other herbals Clinical exper. No data N.A. 1; pilot trials Delay otherTx 
Homeopathic prep Clinical exper. No data N.A. 1; pilot trials Delay otherTx 
Laser acupuncture Stimulate foci for calming Open trial ES 1.0 2; controlled trial Delay burn,other Tx 
EEG biofeedback Suppress theta, increase beta Open & randomized 
wait list Ctrl trials 
p<0.05 3; sham-controlled trial Expense, time 
EMG biofeedback, Lower arousal, muscle tone Randomized trials with ES 1.0-1.3 0 for hypnosis; 4 for Delay other Tx 
relaxat'n, hypnosis  controls p<0.01 EMG/relax'n; cf. med  
Meditation Autonomic effect, Cf. relaxation, wait list p< .05 3; rigorous replica- Delay other Tx 
 focused attention Ctrl, med  tion, sham ctrl  
Mirror feedback Improve deficiency of self- Randomized x-over ES 0.5 3; replication, instruc- May impair non-ADHD 
 focus w. & w/o, cf. controls p<.05 tion to look children 
Channel-specific Basic readiness skills, focus Randomized prev. trial ES 0.9 3; controlled Tx trials Delay other Tx 
perceptual training  with 2 control grps p<0.01  (continued overleaf) 
Vestibular 
stimulation 
Modulate behav., att'n, 
perception 
Open & single-blind 
trials 
ES 0.4-1.2 p 
ns—0.001 
3; randomized 
sham-controlled trials 
Nausea, accident 
Antifungal Tx Gl yeast toxin; breach of 
mucosa 
No data in ADHD; 
other placebo trials 
ES 1.1-3 p < 
0.003 
1; trials in ADHD Medical risk 
Thyroid Tx Thyroid Fx affects AD Sx Placebo trial: 5/8 
GRTH, 1/9 other 
ns if thyr. not 
abnormal 
0 if thyroid normal; 6 if 
thyroid abnormal 
Thyroid toxicity 
Deleading Lead toxicity causes AD Sx Placebo-ctrl trial of 
chelation (=MPH) 
ES 0.7-1.6 p 
0.5-.001 
4 if blood Pb>20; 2 if 
Pb<20; Ctrl trial 
Toxicity of chelator 
* Ratings: 0 = not worth considering further (despite, in the case of amino acids, some evidence of short-lived effect); 
1 = credible hypothesis or collateral support or wide clinical experience, needs pilot data; 2 = promising systematic data, but not prospective trial; 
3 = promising prospective data (perhaps with random assignment to control or objective/blind measures) lacking some important control 
-OR- controlled trial(s) with trends suggesting further exploration; 4 = one significant double-blind controlled trial needing replication 
-OR- multiple positive controlled trials in a treatment not easily blinded; 5 = convincing double-blind controlled evidence but needs further 
refinement (e.g., define target subgroup) for clinical application ; 6 = should be considered established Tx for the appropriate subgroup. 
** The rating would be 6 for patients showing frank deficiency of vitamins, iron, zinc, or other nutrients. 
ES = effect size, Cohen's d; p = probability. 
AD = attention deficit (hyperactivity) disorder; DB = double-blind; Grth = growth; MPH = methylphenidate; PI = placebo; 
Psy = Psychological; Ss = subjects; Sx = symptoms; x-over = crossover 
Table 1. Scientific status of alternate treatments (Tx) for ADHD 
applicable to a smaller subpopulation of patients with ADHD. Therefore, scientific evaluation and 
clinical use of such treatments requires more etiological depth of diagnosis than the 
phenomenological criteria of DSM-IV. 
The treatments summarized here do not exhaust all the alternatives tried or advocated in 
various quarters, but are those for which either peer-reviewed literature or unpublished data could 
be found through two strategies: 1) search on numerous keywords in Medline and Psychlnfo from 
the beginning to 1998; 2) informal contacts with dozens of people—both professional and 
nonprofessional—knowledgeable about or active in various alternate treatments. For lack of 
space, referencing for some of the more popular treatments is more illustrative than exhaustive. 
Elimination Diets (Oligoantigenic or Few-Food Diet) 
At the time of the 1982 NIH Consensus Development Conference on Defined Diets and 
Hyperactivity (NIH, 1982) most elimination diets (defined diets) were popularly known as  
Feingold diets.  The  Feingold (1975) hypothesis had stated that many children are sensitive to 
dietary salicylates and artificially added colors, flavors, and preservatives, and that learning and 
behavior problems, including ADHD, could be ameliorated by eliminating the offending 
substances from the diet. Despite a few positive studies (e.g., Swanson & Kinsbourne, 1981; 
Williams & Cram, 1978), most controlled studies were interpreted by the investigators and 
reviewers/meta-analyzers as nonsupportive of the hypothesis (Conners, 1980; Mattes, 1983; 
Kavale & Forness, 1983). These interpretations were challenged by Feingold (1981) and his 
advocates (Rimland, 1983; Rippere, 1983) on several grounds, including these: 1) narrow 
restriction of tests to food dyes—Feingold (1981) actually anticipated within different children 
hypersensitivity to thousands of different substances, and had merely suggested food colorings as 
a good place to begin controlled studies because of their ubiquity and ease of control; he had not 
meant to equate his diet with elimination of dyes; 2) too low dosage levels of dyes used in 
challenges; 3) arbitrary ignoring of positive findings in certain subgroups; 4) ignoring of animal 
studies. In such equivocal circumstances the 1982 consensus panel called for more controlled 
research. 
Reference Subjects Design Results ES,p 
Eggeretal., 1985 Special diet clinic; HK, 
Conners > 14 
76 Ss open trial few foods; 28 Ss 
placebo x-over challenge 
62/76 improved in trial; 
23/28 better on placebo, 
worse on challenge 
p.001 
Kaplan et al., 1989 Ads, DSM-III, Conners 1 sd, 
physical Sx 
24 preschoolers placebo diet 
x-over (3+4 wk) with all food 
provided; multiple elimination 
Over half had reliable 
behavior improvement, no 
placebo effect 
ES 0.5 p.01 
Pollock & Warner, 
1990 
Ped. allergy clinic, survey; 
selected by parent-observ. 
behv. 
39 Ss placebo-controlled dye 
challenge while on elimination 
diet; only 19 completed 
Food colors small adverse 
effect on Conners rating, not 
globally detected by parent 
ES small p<.01 
Egger et al., 1992 Special diet clinic; HK 
criteria, Conners Index > 15
185 Ss 4-wk open few foods; 40 
Ss parallel random assignm. to 
plac. or enzyme-potentiated 
desensitization (EPD) 
116/185 responded openly 
with reintroduction; 16/20 
with EPD, only 4/20 with 
placebo became tolerant 
p.001 
Carter et al., 1993 Special diet clinic; HK 
criteria, Conners Index > 15
78 Ss open trial few foods; 
23 placebo x-over challenge 
with 
provoking foods; 19 completed 
59/78 improved openly; 
14/19 placebo better 
behavior and Psychological 
test 
p .05-.01 ES 0.6 
Rowe & Rowe, 1994 Hyperactivity referrals 
hospital ped. clinic 
200 Ss 6-wk open dye-free diet; 
34 Ss (23 reactors; 11 uncertain) 
& 20 controls 3-wk daily repeat 
plac. cf. to 6 doses tartrazine 
150/200 improved, relapsed 
on open challenge; 19/23, 
3/11, and 2/20 clear reactors; 
irritable, restless, sleep 
disturb. 
ES 0.8 p.05 
Boris & Mandel, 
1994 
DSM-III-R criteria for 
ADHD 
26 Ss open multiple elimination; 
19 responders 
placebo-controlled DB 
challenge; 16 completed 
19/26 openly responded; 
placebo days significantly bet-
ter than challenge days 
p.001 p.003 ES 1.5 
Schmidt et al., 1997 Hyperactive, disruptive 
inpatients 
49 Ss in DB placebo x-over of 
oligoantigenic & control diet; 36 
also compared to MPH 
12/49 significant behavioral 
improvement cf. control diet; 
16/36 resp. MPH 
 
DB = double-blind; ; MPH = methylphenidate; Pl, plac = placebo 
Table 2. Controlled studies of few-food (oligoantigenic) diets. (ES = effect size, Cohen's d)
Since then, at least 8 controlled studies (Table 2; Breakey, 1997) have demonstrated either 
significant improvement compared to a placebo condition (disguised full diet) (Kaplan, McNicol, 
Conte, & Moghadam, 1989a; Schmidt et al., 1997) or deterioration on a placebo-controlled 
challenge of offending substances after an open diet trial and open challenge to identify the 
substance (Egger, Carter, Graham, Gumley, & Soothill, 1985; Egger, Stolla, & McEwen, 1992; 
Pollock & Warner, 1990; Carter et al, 1993; Rowe & Rowe, 1994; Boris & Mandel, 1994). One 
report (Rowe, 1988) suggested that those who reliably respond to dye challenges constitute a small 
proportion and are more likely the hyperactive-impulsive subtype. The finding of scientifically 
acceptable documentation of efficacy since 1982 appears associated with broadening the range of 
suspected food items, selecting subjects more carefully (e.g., for allergic diathesis), and allowing 
for the timing peculiarities of food sensitivities. A typical oligoantigenic or few-foods diet might 
exclude everything except the following: lamb, chicken, potatoes, rice, banana, apple, brassica 
(cabbage, cauliflower, broccoli, brussels sprouts), cucumber, celery, carrots, parsnip, salt, pepper, 
calcium, and vitamins. A related Tx possibility arises from the documentation of successful 
desensitization to the offending food by enzyme-potentiated desensitization (Esser et al., 1992). 
The main scientific task remaining is to refine the diagnostic characteristics of diet responders and 
delineate what percent of the ADHD population they constitute. Though half or more of enriched 
samples selected for suspicion of food sensitivity seem to respond well under controlled 
conditions, it is not clear what proportion this represents of the whole ADHD population. 
Preliminary evidence suggests that the profile of a probable responder is a middle- or upper-class 
preschooler with atopy and prominent irritability and sleep disturbance, with physical as well as 
behavioral symptoms, and possibly high copper levels (Brenner, 1979), but the definition needs 
more work. 
A related dietary strategy, simple elimination of sugar or candy, has not garnered 
convincing scientific support from repeated placebo-controlled acute challenge studies (Krummel, 
Seligson, & Guthrie, 1996; Wolraich, Wilson, & White, 1995) despite a few encouraging reports 
(e.g., Goldman, Lerman, Contois, & Udall, 1986). Even a well-controlled 3-week trial of a 
sugar-restricted diet found no effect (Wolraich, Lindgren, Stumbo, Stegink, Applebaum, & 
Kiritsy, 1994). Further, most cross-sectional comparisons have not shown excess consumption of 
sugar by children with ADHD compared to controls (Kruesi, Rapoport, Berg, Stables, & Bou, 
1987; Wolraich, Stumbo, Milch, Chenard, & Schultz, 1986; Kaplan, McNicol, Conte, & 
Moghadam, 1989b), though some have found correlations between dietary sugar or refined 
carbohydrate intake and measures of hyperactivity, aggression, or inattention/cognition in 
children either with ADHD (Prinz, Roberts, & Hantman, 1980; Wolraich et al, 1986) or unselected 
for ADHD (Lester, Thatcher, & Monroe-Lord, 1982). It does not appear that sugar or candy 
restriction alone is a widely applicable treatment for ADHD, though it is conceivable that 
continued sugar/candy elimination partially contributes to the documented benefit of the 
few-foods diet for some children with ADHD. 
The side effects, risks, and ripple effects of dietary eliminations remain as controversial as 
the diets themselves. For example, Krummel et al. (1996) warn that coercively enforced parental 
restrictions on the child's diet (or putting the rest of the family unnecessarily on the same diet) 
could worsen family dynamics while Lipton and Mayo (1983) say the nonspecific placebo effects 
are beneficial to families. There is some concern about breadth of nutrient intake on the one hand, 
and on the other hand the comment that eliminating junk foods improves essential nutrient intake 
(Rimland, 1983). On balance, it seems the main risk associated with dietary elimination is the 
delay of more effective treatment if the child is a nonresponder. 
Immune Therapy 
Food-borne allergy may not be the only immunological consideration for etiological 
subgroups of ADHD. In 50 children (mean age 9) with pediatric autoimmune disorders associated 
with streptococcal group A beta-hemolytic infection (PANDAS), Swedo et al. (1998) found a 40 
percent rate of ADHD. It is not clear what proportion of an unselected ADHD sample would have 
PANDAS. However, Hagerman and Falkenstein (1987) reported twice the rate of otitis media in 
hyperactive subjects compared to controls, suggesting either immune problems or greater 
exposure to infectious agents. Swedo et al. planned a trial of immune therapy as Tx of the 
neuropsychiatric disorders, but no results are available as of this writing. Immunological therapy 
targeting Candida (Palacios, 1976, 1977) might be a logical alternative to antifungal therapy for 
hypothesized sensitivity to gastrointestinal yeast overgrowth, but apparently has not been 
proposed for ADHD. For food sensitivities, Egger et al. (1992) have reported significant (p < 
0.001) benefit from enzyme-potentiated desensitization in a double-blind placebo-controlled trial. 
Nutritional Supplements 
In a sense, nutritional supplementation is the opposite of elimination or few-foods diets, 
which are based on the assumption that something in the diet is noxious and should be removed. 
Supplementation is based on the assumption that something is lacking in the diet in optimal 
amount and should be added. Both macronutrients (amino acids, lipids, carbohydrates) and 
micronutrients (vitamins and minerals) have been proposed as Tx for ADHD. 
Amino Acid Supplementation 
Amino acid supplementation is theoretically supported by report of low levels of amino 
acids in ADHD, including the precursors of catecholamines and serotonin (Bornstein, Baker, 
Carroll, King, Wong, & Douglass, 1990; Baker, Bornstein, Rouget, Therrien, & van Muyden 
1991). Stein and Sammaritano (1984) reported that compared to matched normals with similar 
dietary intake, 8- to 10-year-old hyperkinetic boys excreted more nitrogen (JES = 5, p < 0.01) and 
showed different distribution patterns of excretion, flux, and protein synthesis. Several open and 
controlled studies have reported a short-term benefit from tryptophan, tyrosine, or phenyalanine 
supplementation (Nemzer, Arnold, Votolato, & McConnell, 1986; Reimherr, Wender, Wood, & 
Ward, 1987; Wood, Reimherr, & Wender, 1985a). However, no lasting benefit beyond 2-3 months 
has been demonstrated since tolerance usually develops (Wood, Reimherr, & Wender, 1985b), 
and even short-term benefit was not found in some studies (Eisenberg, Asnis, van Praag, & Vela, 
1988; Ghose, 1983; Zametkin, Karoum, & Rapoport, 1987). Further, such supplementation, while 
originally considered benign, may carry some risk (Pakes, 1978; Sidransky, 1997; Sternberg, 
1996). The best-publicized risk was the 1989 epidemic of eosinophilia-myalgia linked to 
tryptophan use. However, this association was more likely due to impurities rather than to the 
tryptophan itself (Sidransky, 1997; Williamson, Tomlinson, Mishra, Gleich, & Naylor, 1998), and 
it may have partly resulted from circular diagnostic practice (Blackburn, 1997; Wagner, Elmore, 
& Horwitz, 1996). In sum, amino acid supplementation does not appear a promising area to 
explore further, though protein-rich diets might be explored as a specific correction of the reported 
nitrogen-wasting metabolic aberrations or as palliation of alleged hypoglycemia. 
Essential Fatty Acid Supplementation 
Neuronal membranes are composed of phospholipids containing large amounts of 
polyunsaturated fatty acids, especially the n-3 and n-6 (or omega-3 and omega-6) acids (with the 
first unsaturated bond 3 or 6 carbons, respectively, from the noncarboxyl "tail" of the molecule), 
which humans cannot manufacture de novo and hence are "essential" in the diet. Essential fatty 
acids (EFA) are also metabolized to prostaglandins and other eicosanoids, which modify many 
metabolic processes. Lab animal behavior can be manipulated by varying the quantity and quality 
of essential fatty acids (Arnold, Kleykamp, Votolato, Gibson, & Horrocks, 1994). Juvenile and 
young adult monkeys with long-term n-3 fatty acid deficiency show increased activity, and both 
human and monkey infants show changes in visual attention with n-3 deficiency (Neuringer, 
1998). In adult humans, n-6 EFAs correlated positively and n-3 EFAs correlated negatively with 
cerebral-spinal-fluid 5-HIAA and HVA, the metabolites respectively of serotonin and dopamine 
(Hibbeln, Linnoila, Umhau, Rawlings, George, & Salem, 1998). Both the n-3 series (progenitor 
alpha-linolenic acid) and the n-6 series (progenitor linolenic acid) have been reported to be 
significantly lower in children with ADHD than in comparison controls (Mitchell, Lewis, & 
Cutler, 1983; Mitchell, Aman, Turbott, & Manku, 1987; Stevens et al., 1995). Even total serum 
free fatty acids were lower in ADHD, with ES = 2.4, p < .001 (Bekaroglu et al., 1996). Aggression 
has been significantly inhibited in young adults by docosohexaenoic acid of the n-3 series 
(Hamazaki et al., 1996). Two double-blind placebo controlled trials of gamma-linolenic acid (n-6 
series, evening primrose oil) supplementation yielded equivocal results from ADHD subjects not 
selected for low n-6 acids (Aman, Mitchell, & Turbott, 1987; Arnold, Kleykamp, Votolato, 
Taylor, Kontras, & Tobin, 1989); in one trial, the serum triglyceride gamma-linolenic acid 
correlated inversely with Conners Rating Scale scores (Arnold et al., 1994). A controlled pilot trial 
of n-3 supplementation in ADHD subjects selected for symptoms of EFA deficiency (but not for 
specific n-3 deficiency in plasma) showed a trend of advantage for the supplement despite a huge 
placebo effect (pre-post ES 1.8 vs. 1.4), and changes in serum phospholipid n-3 acids correlated 
negatively with changes in Conners Rating Scale scores (Burgess & Stevens, 1998). In 
preliminary data on 70 subjects not selected for deficiency, Voight, Llorente, Jensen, Berretta, 
Boutte, and Heird (1998) found no effect of docosohexaenoic acid (n-3) compared to placebo. In 
sum, the data suggest further controlled trials in patients selected for low serum levels of the 
specific EFA supplemented. 
Glyconutritional Supplements 
Glyconutritional supplement contains basic saccharides necessary for cell communication 
and formation of glycoproteins and glycolipids: glucose, galactose, mannose, N-acetylneuraminic 
acid, fucose, N-acetylgalactosamine, and xylose. Only the first two are abundant in the ordinary 
diet. In an open trial of glyconutritional and phytonutritional (flash freeze-dried fruits and 
vegetables) supplementation with 17 ADHD subjects, Dykman and Dykman (1998) found 
significant (p <.05 - p <.001) reductions in parent SNAP-IV ratings of inattention, 
hyperactivity-impulsivity, and oppositional symptoms, with similar trends on teacher ratings. In a 
second open trial of the same supplements in 18 children, Dykman and McKinley (1997) found 
reductions in parent inattention ratings from 2.47 to 2.05 (p < .06) and hyperactivity-impulsivity 
ratings from 2.23 to 1.54 (p < .003), sustained for 6 weeks. Placebo-controlled trials are needed. 
Vitamin Supplementation 
Three strategies for vitamin supplementation are: 1. RDA multivitamin preparations; 2. 
Megavitamin multiple combinations; and 3- Megadoses of specific vitamins. 
The first strategy is noncontroversial but there is no research on effects in diagnosed 
ADHD even though some reports suggest mild deficiencies in diet and blood levels that might be 
addressed. However, in a randomly assigned double-blind placebo-controlled trial of RDA 
vitamin and mineral supplementation in 47 6-year-old children not selected for ADHD, Benton 
and Cook (1991) found an 8.3-point IQ advantage (p < .001). This IQ advantage is represented 
mainly in nonverbal ability, increased concentration and decreased fidgeting on a frustrating task 
(p < .05), and advantage on a reaction time task reflecting sustained attention (ES = 1.3, p < .05). 
These data warrant a controlled trial in ADHD, although the benefit may be confined to a 
subgroup with poor diets (Benton & Buts, 1990). 
The second strategy, megavitamin multiple combinations, has not been found effective in 
double-blind placebo-controlled short (2 week) and longer (up to 6 month) trials examining 
ADHD and the related comorbidity of learning disorder (Arnold, 1978; Haslam, Dalby, & 
Rademaker, 1984; Kershner & Hawke, 1979). The researchers who conducted those trials have 
been challenged on the basis of not using the correct mix of vitamins and minerals. Also, Kershner 
and Hawke's (1979) study used a preliminary elimination diet that removed so much deviance that 
the vitamin trial suffered from a ceiling effect. On balance, megavitamin multiple combinations do 
not seem worth pursuing. 
The third strategy, judicious use of single vitamins in megadosage to alter neural 
metabolism in specific ways, is actually more like psychopharmacology and has not been 
adequately explored despite some encouraging early reports (e.g., Coleman et al., 1979; Brenner, 
1982). 
Though megavitamins, like any pharmacological intervention, pose some risk, the 
hepatotoxic (Haslam et al., 1984; Shaywitz, Seigel, & Pearson, 1977), neuropathic (Schaumburg 
et al., 1983; Bernstein, 1990; Snodgrass, 1992), and other (Sato, Taguchi, Maeda, & Yoshikawa, 
1993; Snodgrass, 1992; Anonymous, 1984) dangers may be overstated in some quarters: the 
hepatotoxicity reported by Shaywitz et al. (1977) resulted from accidental overdosage of vitamin 
A, not from megavitamin therapy; the doses of pyridoxine (B6) reported to cause neuropathy 
(generally 2 g or more a day) are higher than the doses usually recommended in most megavitamin 
regimens; and pyridoxine toxicity seems largely reversible on cessation of supplementation. In 
intermediate doses (e.g., 100-150 mg/day), pyridoxine is more likely to counteract toxicity of 
other ingestants, including drugs, food colors, and excess other nutrients than to be toxic itself 
(Brown, Mallett, Fiser, & Arnold, 1984; Bernstein, 1990; Houben & Penninks, 1994; Durlach, 
Durlach, Bac, Bara, & Guiet-Bara, 1994). Except for rare genetic disorders, RDA multivitamins 
do not appear to pose any risk other than sensitivity to added coloring or flavors. 
Mineral Supplements 
The main mineral candidates for supplementation are iron, zinc, magnesium, and calcium, 
all of which have been reported deficient in subjects with ADHD compared to matched controls 
(Kozielec, Starobrat-Hermelin, & Kotkowiak, 1994). 
Iron Supplementation. 
Iron is a co-enzyme in anabolism of catecholamines. In an open 30-day supplementation 
trial with 17 nonanemic ADHD boys age 7-11, Sever, Ashkenazi, Tyano, and Weizman (1997) 
found improvement in Conners Rating Scale parents' scores from 17.6 to 12.7 (ES = 1.0), but not 
in teacher ratings. In a double-blind placebo-controlled trial in 73 teenage nonanemic but 
iron-deficient girls, Bruner, Joffe, Duggan, Casella, and Brandt (1996) found improvements in 
verbal learning and memory. In a trial of gastroprotected ferritin in 33 iron-deficient children, 
Burattini et al. (1990) found a decrease of hyperactivity. Iron supplementation merits further 
study, with focus on whether any benefit found is confined to those with laboratory evidence of 
iron deficiency, and with due concern for possible toxicity of excess iron. 
Zinc Supplementation. 
Zinc is a cofactor for 100 enzymes, many involved in neural metabolism, and is necessary 
for fatty acid absorption and for production of melatonin, which helps regulate dopamine function 
(Sandyk, 1990). Animal data suggest involvement of zinc deficiency in hyperactivity (e.g., Halas 
& Sandstead, 1975; Sandstead, Fosmire, Halas, Jacob, Strobel, & Marks, 1977), and human 
deficiency syndrome includes concentration impairment and jitters (Aggett & Harries, 1979). Zinc 
has been reported deficient in ADHD compared to controls, with ES up to 2.4 (p < .001) 
(Bekaroglu et al., 1996; Toren et al, 1996). However, McGee, Williams, Anderson, 
McKenzie-Parnell, and Silva (1990) did not find a significant correlation of parent and teacher 
hyperactivity ratings with hair or serum zinc in the epidemiologic Dunedin sample. Arnold, 
Votolato, Kleykamp, Baker, and Bornstein (1990) reported data suggesting that stimulant 
response may depend on adequate zinc nutriture. Sandyk (1990) speculated that stimulants might 
work via their reported propensity for increasing melatonin production, a process dependent on 
zinc. Despite clinical advocacy of zinc supplementation, no systematic prospective trials could be 
found. The obvious need is a placebo-controlled double-blind trial of RDA zinc supplementation 
with pre-treatment assessment of zinc status to determine whether zinc deficiency is a prerequisite 
for any benefit found. Though excess zinc can cause white cell aplasia (Forsyth & Davies, 1995), 
this does not appear to be a risk for RDA doses. 
Magnesium Supplementation. 
Magnesium deficiency can cause a wide spectrum of neurological and psychiatric 
disturbance and can result from a wide variety of causes, including increased requirement during 
childhood (Flink, 1981). Kozielec and Starobrat-Hermelin (1997) examined hair, red cell, and 
serum magnesium of 116 children age 9-12 with ADHD and found 95 percent (34 percent by 
serum alone) deficient in magnesium; there was no control group other than lab norms. They 
assigned 50 children age 7-12 with DSM-IV ADHD and magnesium deficiency to 6 months open 
supplementation with about 200 mg/day (in addition to usual treatment) and 30 similar controls 
were assigned to usual treatment without magnesium; it was not clear whether assignment was 
random; the supplemented group significantly decreased their Conners' Rating Scales parent and 
teacher ratings (ES = 1.2-1.4) compared to the control group (Starobrat-Hermelin & Kozielec, 
1997). Thus, magnesium supplementation merits a randomized placebo-controlled double-blind 
trial and replication by other investigators. Dosage of supplementation may be important, because 
animal work suggests a U-shaped behavioral dose-response curve (Izenwasser, 1986). Therefore, 
it is possible that children not deficient in magnesium could be made worse by supplementation. 
Further, doses >10 mg/kg/day can cause toxic symptoms (Durlach et al., 1994). 
Herbal and Homeopathic Treatments 
Many herbal and homeopathic remedies have been proposed for use in ADHD. No 
systematic data regarding ADHD efficacy could be found for Calmplex, Defendol, Gingko biloba, 
hypericum, or pycnogenol. Although a case report of successful pycnogenol treatment was found 
(Heimann, 1999), a representative of one of the companies selling pycnogenol said they had 
dropped ADHD as an indication because it doesn't work on ADHD. The first few remedies listed 
may be worth pilot trials based on clinical experience. There are more data for traditional Chinese 
herbals. 
In a randomly assigned open trial, Zhang and Huang (1990) compared a Chinese herbal 
cocktail (80 Ss) to methylphenidate 5-15 mg b.i.d. (20 Ss) for 1-3 months; 23/80 herbal cocktail 
cases were "cured" (disappearance of all clinical symptoms and no recurrence for 6 months) 
compared to 6/20 taking methylphenidate. Including improved cases, the effectiveness rates were 
86 percent vs. 90 percent; the groups did not differ except for lower side effects and greater IQ rise 
in the herbal group. In an open trial with 100 hyperkinetic children, Wang, Li, and Li (1995) found 
an effectiveness rate of 94 percent, including reduction of hyperactivity, improved attention, and 
improved academics resulting from the administration of the herbal Tiaoshen Liquor. In another 
open trial in 66 hyperkinetic children, Sun, Wang, Qu, Wang, Fang, and, Zhang (1994) found an 
effectiveness rate of 85 percent with Yizhi wit-increasing syrup, including significant 
improvement in behavior, school records, and soft neurological signs. Shen and Wang (1984) 
reported that 8 children with minimal brain dysfunction showed the same decrease in urinary 
3-methoxy-4-hydroxyphenylglycol from Chinese herbal treatment as 38 children did from 
methylphenidate. Thus, the open pilot data warrant placebo-controlled double-blind trials of 
Chinese herbals. 
Acupuncture 
Despite the popularity of acupuncture, no published systematic data on its efficacy with 
ADHD could be found. Loo (1998), in unpublished, preliminary, pre-post, single-blind data from 
students in grades K-3, found improvements in Conners' Rating Scale 10-item scores by teachers 
(n = 7) from 17.0 to 12.0, and in analogous parent scores (n = 6) from 23.1 to 15.5. She noted that 
children with the most severe ADHD could not cooperate with the Tx. 
EEG Biofeedback 
Electroencephalographic (EEG) biofeedback involves inducing sensorimotor 12-15 Hertz 
or 15-18 Hertz beta band EEG rhythms and suppressing theta rhythms by visual and auditory 
feedback. Research into the efficacy of EEG biofeedback with ADHD arose from 1) the 
observation that some ADHD children have more theta and less beta rhythm than controls and 2) 
animal work that demonstrated reduced motor activity associated with sensorimotor rhythm 
(Shouse & Lubar, 1978; Mann, 1992). There are several promising pilot trials. Lubar (1991) and 
Lubar and Shouse (1977) reported that in a single-subject ABA design, 4 hyperactive children 
selected for low arousal showed better behavior and work habits without stimulant at the end of all 
treatment (ABA) than at the beginning with or without stimulant and their unmedicated level of 
undesirable behaviors dropped by over half to the level of the normal controls; three of them 
showed synchrony of behavior with the ABA shifts. An uncontrolled open trial with 37 
hyperactive children yielded significant grade-point and achievement score improvements (Lubar, 
1991). In an intensive summer treatment regimen, 12 children who showed EEG changes also 
improved on significantly more Tests of Variables of Attention scales than did 7 who failed to 
show EEG changes (Lubar, Swartwood, Swartwood, & O'Donnell, 1995). Linden, Habib, and 
Radojevic (1996) randomly assigned 18 children with DSM-IIIR ADD/ADHD to either a waiting 
list (n = 9) or to 40 EEG biofeedback sessions over a 40-week period. The treated group showed a 
9-point IQ rise compared to the waiting list rise of <1 point (p < 0.05) and a 28 percent reduction 
on the inattention score of the SNAP (Swanson, Nolan, and Pelham scale with DSM ADHD 
symptoms on Conners metric) compared to a 4 percent increase for the waiting list group (p <. 05). 
Thus, this treatment merits a sham-controlled randomized trial (Arnold, 1995). 
EMG Biofeedback, Relaxation Training, and Hypnosis 
These three related Tx modalities are typically used in some combination. The few 
published data on hypnotherapy alone for treatment of ADHD are discouraging: Calhoun and 
Bolton (1986) were unsuccessful in three attempts each to hypnotize 10 of the 11 hyperactive chil-
dren they tried it with. Breathing control alone, used not only in hypnosis but also in meditation 
and relaxation, showed no difference from sham training in 6 hyperactive intelligent 6-8-year-olds 
(Simpson & Nelson, 1974). However, the hypnotic techniques of imagery and progressive 
relaxation have often been incorporated into successful EMG biofeedback protocols. 
There are more literature citations for EMG than for EEG biofeedback (Lee, 1991), but 
they are generally older, suggesting a recent waning of interest. Denkowski, Denkowski, and 
Omizo (1983) randomly assigned hyperactive junior high school boys to six 25-minute 
EMG-assisted relaxation training sessions (n = 24) or to a control condition (n = 24); the treated 
group attained significantly higher reading and language performance and made a significant 
internal shift in locus of control. In 10 hyperactive boys age 6-12, Dunn and Howell (1982) found 
significant improvement in behavior observations, parent ratings, and psychological tests after 10 
relaxation training sessions but none after 10 neutral sessions. Omizo and Michael (1982) 
randomly assigned hyperactive boys age 10-12 to either four sessions of EMG 
biofeedback-induced relaxation (n = 16) or sham treatment (n = 16) of equal length; compared to 
the sham, the relaxation induced significant improvements in attention and impulsivity as 
indicated from results on the Matching Familiar Figures test (ES = 1.0 to 1.3, p < .01). Krieger 
(1985) found in 27 children age 7-11 with DSM-III Attention Deficit Disorder-Hyperactivity 
(ADD-H) significant improvement on Conners' parent and teacher rating scales compared to an 
equal-n matched wait list control group. Success is largely moderated by baseline locus of control 
(Denkowski et al., 1984). However, the reports were not uniformly positive; Irving (1987) found 
in 24 boys age 6-12 that EMG biofeedback/relaxation added nothing to stimulant benefit, but 
stimulant added to biofeedback benefit. Denkowski and Denkowski (1984) assigned 45 
hyperactive elementary school children to eight sessions of group progressive relaxation training, 
relaxation training with frontalis biofeedback, or placebo (listening to taped children's stories); the 
trend of advantage for the two active treatments was not significant at the group size of 15. Cobb 
and Evans (1981) reviewed the then extant literature and concluded that there was no evidence that 
biofeedback was superior to "more conventional treatments" for learning or behavior disorders. 
Nevertheless, the data on balance suggest that despite recent neglect, EMG 
biofeedback-facilitated relaxation training merits further study for children with ADHD who do 
not benefit from stimulants or whose parents object to stimulants. 
Meditation 
Meditation, though resulting in relaxation, is different from the preceding treatments in not 
directly targeting relaxation, but achieving it indirectly. Kratter (1983) randomly assigned 24 
children age 7-12 with DSM-III ADD-H to either meditation training, progressive relaxation, or 
waiting list control, with 4 weeks of twice-weekly sessions; both active treatments but not waiting 
list reduced impulsivity and improved scores on parent behavior scales but not teacher scales; only 
meditation training showed significant improvement on a test assessing selective attention. 
Moretti-Altuna (1987) randomly assigned 23 boys age 6-12 with ADD-H to meditation training, 
medication, or standard therapy; meditation showed significant advantage in classroom behavior 
but not in parent ratings or psychological tests. Thus, meditation warrants further study. 
Mirror Feedback 
Mirrors have been proposed as a way of increasing self-control and attentional focus by 
increasing self-focus in children with ADHD (Zentall, Hall, & Lee, 1998). In a single-blind 
randomized trial on 16 hyperactive-inattentive (HI) and 27 normal middle-school students, a word 
puzzle that differentiated the HI from the control subjects with an effect size of 0.75 (p < .05) in 
the no-mirror condition showed a between-groups ES of only 0.2 (n.s.) with a mirror in front of the 
child as he/she worked. The mirror condition improved the performance of the HI Ss by half the 
no-mirror difference between groups. With no instruction about the mirror, the His who actually 
looked in the mirror scored equal to the no-mirror scores of the controls. This intervention carries 
a risk associated with diagnostic validity: the normal controls showed a trend of performance 
decrement with the mirror, especially if they looked in it (Zentall et al., 1998). Though not 
applicable to a regular classroom, it may be useful in learning carrels specifically used by ADHD 
students and for homework, and deserves further trials. 
Perceptual Stimulation/Training 
Perceptual and sensory stimulation and training include a wide variety of modalities, some 
with few or no data. The literature search found no systematic data on sensorimotor integration or 
optometric training for ADHD despite their widespread use. Neither were studies in ADHD found 
for massage, which has documented efficacy in other applications (Field, Morrow, Valdeon, 
Larson, Kuhn, & Schanberg, 1992). The Interactive Metronome (1998) provides perceptual-motor 
concentration training with biofeedback about accuracy from motion sensors as the child taps to 
the beat provided by the program; open trials show improvements in timing that correlate at 
0.2-0.4 with teacher ratings of attention, but there are no controlled data (Interactive Metronome, 
1998). 
In a single-blind prevention paradigm, Arnold et al. (1977) randomly assigned matched 
trios and quads of first-graders selected for vulnerability on a perceptual screening battery to either 
6 months of channel-specific perceptual training (n = 23), the same length of regular academic 
tutoring (n = 23), or to no-contact control (n = 40); at 1-year follow-up, the trained group 
surpassed both control groups in blinded teacher Conners' ratings (ES = 1.0, p <. 01), Wide Range 
Achievement Test (WRAT) reading achievement (12.6 standard points difference, p < 0.01), and 
Wechsler IQ (8 points difference, p < 0.05), though baseline measures were not different. 
Mulligan (1996) reported significant impairment of vestibular processing in 309 children 
with ADHD compared to 309 matched children without ADHD (p < 0.01). Both the semicircular 
canals and the otolithic utricles/ saccules of the vestibular system activate the autonomic nervous 
system (Yates, 1992). Previc (1993) suggests that the utricles/otoliths produce noradrenergic 
sympathetic brain stimulation while the semicircular canals produce cholinergic parasympathetic 
brain stimulation. In a single-blind crossover in 18 children with DSM-II hyperkinetic reaction, 
Bhatara, Clark, Arnold, Gonsett, and Smeltzer (1981) found improvement in Conners' teacher 
ratings from rotational vestibular stimulation of the semicircular canals compared to a sham 
condition (p <. 05), with benefit mainly confined to the 14 children below age 10 and those 
without comorbid conduct disorder. In another single-blind crossover with 12 children identified 
through teacher scale screening, Arnold, Clark, Sachs, Jakim, and Smithies (1985) found an ES of 
0.5 between vestibular rotational stimulation alone and two control conditions (missing 
significance at the sample size), compared to an ES of 0.2 between visual rotational stimulation 
alone and the same control conditions in a similar group of 18 children. The Comprehensive 
Motion Apparatus provides vestibular stimulation in all vectors through complex motion, 
stimulating both semicircular canals and otoliths; an open trial in 14 dyslexic children (mean age 
12±2.6 yr.) showed pre-post improvement in parent rating of attention (ES = 1.5, p < .003) and 
objective cognitive/achievement tests (ES 0.4-1.2, p 0.05-0.001) (Stillman, 1998). Thus, 
stimulation and/or training of specific perceptual channels merits further research in controlled 
trials, especially targeting subgroups who test deficient in the particular perceptual modality. 
Antifungal Treatment 
Treatment with antifungal agents such as nystatin (in combination with sugar restriction 
and other measures) is advocated by Crook (1985, 1989, 199D and others on the hypothesis that 
repeated antibiotic use for otitis media changes intestinal flora, allowing yeast overgrowth, which 
compromises immune function and changes the gut mucosal barrier to allow absorption of food 
antigens. Several components of this hypothesis are supported by collateral documentation from 
other fields (e.g., Hagerman & Falkenstein, 1987; Nsouli, Nsouli, Linde, O'Mara, Scanlon, & 
Bellanti, 1994; Vargas, Patrick, Ayers, & Hughs, 1993), and the hypothesis would make sense of 
the reported association of chronic sugar intake with ADHD symptoms (e.g., Prinz et al., 1980) 
without acute effects, in that sugar could promote yeast overgrowth chronically without showing 
acute effects on behavior. However, this hypothesis is not supported by any systematic 
prospective trial data in ADHD. A trial of nystatin alone for fatigue, premenstrual tension, 
gastrointestinal symptoms, and depression associated with Candida vaginitis was reported 
negative (Dismukes, Wade, Lee, Dockery, & Hain, 1990); but Crandall (1991) challenged this 
conclusion on methodological grounds and Truss (1991), reanalyzing the published crossover 
data, found an advantage for double nystatin (oral and vaginal) over double placebo significant at 
p < 0.01 (2-tailed). A systematic randomly assigned trial in ADHD should be carried out, 
preferably double-blind placebo-controlled and accompanied by the sugar restriction and other 
supportive measures recommended by the advocates of this treatment. 
Thyroid Treatment 
Despite initial enthusiasm about resistance to thyroid hormone as a key to a large 
proportion of ADHD, this genetic syndrome appears extremely rare in ADHD samples. The same 
studies, however, reveal a rate of other thyroid dysfunction ranging from 2 percent to 5 percent 
(e.g., Weiss, Stein, Trommer, & Refetoff, 1993; Valentine, Rossi, O'Leary, Parry, Kurinczuk, & 
Sly, 1997), and the rate may be higher in those with comorbid mood disorder (West et al., 1996). 
In children with thyroid dysfunction, the thyroid status seems related to attentional and 
hyperactive-impulsive symptoms (Rovet & Alvarez, 1996; Hauser, Soler, Brucker-Davis, & 
Weintraub, 1997). In a double-blind placebo crossover trial of thyroid supplementation, only 1 of 
9 children with ADHD and normal thyroid function improved compared to 5 of 8 with ADHD and 
resistance to thyroid hormone (Weiss, Stein, & Refetoff, 1997). Thus, thyroid treatment does not 
seem promising in ADHD children with normal thyroid function, but would seem the treatment of 
choice for those with thyroid dysfunction. Therefore, all children with ADHD should be screened 
for historical and physical exam signs of possible thyroid dysfunction (Weiss & Stein, 1998). 
Deleading 
Animal data (e.g., Silbergeld & Goldberg, 1975) document hyperactivity as one symptom 
of chronic lead poisoning, and suggest that lead-induced hyperactivity depends on lead levels and 
can be reversed by chelation (Gong & Evans, 1997). In humans (e.g., David, Hoffman, Sverd, & 
Clark, 1977) the blood level considered toxic for subtle neuropsychiatric symptoms has declined 
with increasing knowledge: in 1991 the Centers for Disease Control adopted 10 µg/dL for 
developing children, and some authors place it as low as single digits (Kahn, Kelly, & Walker, 
1995). Whether or not tissue lead levels correlate with behavioral and cognitive measures is the 
subject of some controversy, partly depending on the sample size, consequent power, and range of 
lead burden in the population studied (Gittleman & Eskanazi, 1983; Needleman et al., 1979). 
David, Hoffman, Sverd, Clark, and Voeller (1976) openly treated 13 children who had 
hyperkinetic reaction and blood lead levels >25 µg/dL with penicillamine (CaEDTA if allergic to 
penicillin); the 7 with no other probable medical cause of their hyperkinesis improved in teacher 
hyperactivity rating (ES = 1.4, p < 0.01) and parent hyperactive-impulsive rating (ES = 2.2, p < 
.0.05), but not significantly in teacher inattention rating (ES = 0.6), while the 6 with another 
probable medical cause did not improve. In a double-blind placebo-controlled 12-week trial, 
David, Hoffman, Clark, Grad, and Sverd (1983) randomly assigned hyperactive children with 
"minimally elevated lead levels" (mean 28±6 µg/dL) to either penicillamine plus methylphenidate 
placebo (n = 22), methylphenidate (5-40 mg/day) plus penicillamine placebo (n = 11), or double 
placebo (n = 11): compared to placebo, penicillamine improved Conners' teacher hyperactivity 
scores (ES = 1.6, p < 0.001), parent Werry-Weiss-Peters hyperactivity scores (ES = 0.7, p < 0.05), 
and Clinical Global Impression (ES = 1.4, p < 0.01); across measures the penicillamine group did 
nonsignificantly better than the methylphenidate group. Thus, it appears that deleading would be 
the treatment of choice for children with ADHD who have blood lead elevations in the range 
treated by David and associates. How low a blood lead level this treatment should extend to is a 
research question of high priority. 
Recommendations for Clinical Practice 
There seem to be four categories of alternatives in treating ADHD (alternatives being 
defined as treatments other than psychoactive medication and psychosocial/behavioral 
treatments). 
Category 1 
Many of the treatment alternatives for ADHD are in various stages of scientific 
exploration, ranging from hypothesis through pilot data, and therefore do not enjoy the data base 
necessary for making clinical practice recommendations. These treatments are neither proven nor 
found lacking in definitive controlled trials. Included in this category are essential fatty acid 
supplementation, glyconutritional supplementation, RDA vitamins, single-vitamin megadosage, 
herbals, homeopathic remedies, Laser acupuncture, EEG biofeedback, mirror feedback, 
channel-specific perceptual training, vestibular stimulation, antifungal therapy, and some types of 
immune therapy. 
Category 2 
A few of the alternatives proposed have been demonstrated to be probably ineffective or 
possibly dangerous. Prominent among these are the various forms of megavitamin multiple 
combinations (as opposed to RDA multivitamins) which have not only failed to show benefit in 
controlled studies, but also carry a mild risk of hepatotoxicity and peripheral neuropathy. Thus, 
megavitamin multiple combinations have enough evidence to warn physicians and the public 
away from their indiscriminate use. Megadosage of one or two specific vitamins may be more 
effective, but has not been adequately explored for ADHD. Amino acid supplementation (except 
for remedy of specific deficits), though possibly effective in the short term, does not seem to be a 
practical long-term treatment; there may also be some risk. Simple sugar restriction has not been 
found effective in most controlled studies, but does not appear to pose any risk. 
Category 3 
Some of the alternatives are ineffective or dangerous for the majority of children with 
ADHD, but clearly indicated by clinical common sense for those with the etiology targeted. For 
example, chelation ("deleading") would be the preferred treatment for patients with demonstrated 
blood elevations of lead (or other heavy metals), but would be irrelevant (at our current state of 
knowledge) and pose some risk for a child with blood lead below 10 µg/dL. For the 2-5 percent of 
children with ADHD who have thyroid abnormality, correction of the thyroid problem should 
logically be the first line of treatment, but is not indicated for the majority with normal thyroid 
function. For children with demonstrated deficiencies of any nutrient (e.g., zinc, iron, magnesium, 
vitamins), correction of that deficiency is the logical first-line treatment. It is not clear what 
proportion of children have such a nutritional deficiency, but it may be higher than generally 
suspected because of the confluence of two factors: 1) Many children have a preference for highly 
processed sugary foods lacking in nutritional balance and succeed in subsisting on these despite 
parents' intentions to the contrary, and 2) many pediatricians and parents subscribe to the axiom 
that if one eats a balanced diet, vitamin supplementation is not necessary; since they intend for 
their children to eat a balanced diet, they overlook the first factor and conclude that vitamin pills 
are not necessary. 
Category 4 
A few of the alternatives have rather convincing scientific evidence or other features 
suggesting that they should be implemented where appropriate and practical. Chief among these is 
the few foods (oligoantigenic) diet, for which there is good evidence of efficacy in the subgroup 
with sensitivity to foods. Note that the proportion of diagnosed ADHD children who have food 
sensitivities has not been empirically established, but is certainly a minority, perhaps as low as 5 
percent, but more likely double digits. The diet can be rather onerous, and the desensitization 
procedure may be more practical in many cases. A more generally applicable treatment with 
reasonable evidence of efficacy is the combination of relaxation training and EMG biofeedback, 
which is relatively inexpensive; some studies report results with only 4-8 sessions and group 
administration is feasible. Meditation, though not definitively proven in ADHD, has been reported 
beneficial in two small comparison trials and is accepted for other areas of health. It seems to carry 
no risk. 
Approach to Selecting Treatment 
Since many of the alternate treatments are targeted to specific etiologies, they should 
paradoxically be considered (not necessarily implemented) first during the diagnostic evaluation, 
which should consider etiologies for the symptoms. Only after etiologies amenable to specific 
treatment are ruled out should the standard, generic treatments (psychotropic medication and 
behavioral Tx) be implemented as the main therapeutic thrust. Therefore, a good history and 
physical exam will check for signs of thyroid dysfunction, allergic history, food intolerance, 
dietary balance/deficiency, and general medical problems. As individually indicated, a complete 
blood count and electrolytes/minerals are desirable as a general screen and to pick up mineral 
deficiencies. In areas with high rates of subclinical lead poisoning, a serum lead should be done. 
More complete screening for all minerals (e.g., iron, zinc) could be justified, especially if there is 
any question from the dietary history. In questionable cases, a therapeutic trial may be indicated. 
Recommendations for Future Research 
Future research efforts should a) mount definitive trials and replications of promising 
treatments that may have some advantage over the standard treatments if proven effective, b) 
mount controlled clinical trials of treatments for which a controlled trial is easy and cheap 
(Arnold, 1995), c) mount open pilot trials of well-considered hypotheses for which there are no 
pilot data and for which a controlled trial would be expensive or difficult, and d) define subgroups 
(characteristics and proportion of diagnosed ADHD children) appropriate for treatments for which 
efficacy has been demonstrated. 
Replications and Definitive Trials 
The following treatments have either promising enough pilot data to warrant a definitive 
clinical trial or a controlled study deserving replication by other investigators: Chinese herbals, 
EEG biofeedback, mirror feedback, channel-specific perceptual training, vestibular stimulation 
(e.g., comprehensive motion machine), magnesium supplementation, enzyme-potentiated 
desensitization for food allergies, meditation, and possibly n-3 essential fatty acid 
supplementation in patients with low plasma levels. 
Controlled Trials that are Cheap/Easy 
It would be easy enough and cheap enough to do a controlled trial of the following that it 
makes sense to take this step directly in order to settle the issue: glyconutritional supplementation, 
RDA multivitamins, zinc RDA supplementation, antifungal therapy (with sugar restriction). 
Pilot and Open Trials 
The following need some pilot data to tell whether a controlled clinical trial is indicated: 
homeopathic remedies, nonChinese herbals, acupuncture, chronic sugar restriction, massage. 
Definition of Applicable Subgroups of ADHD 
The following treatments, with either convincing controlled-trial evidence of efficacy or 
else common-sense clinical justification for appropriate patients, need better definition of the 
appropriate subgroups of ADHD patients: few foods (oligoantigenic) diets, chelation (what is the 
critical blood level of lead responsive to chelation?), iron supplementation (how iron-deficient, or 
is deficiency even needed?), EMG biofeedback/relaxation. 
The most basic recommendation for future research on treatment alternatives for ADHD is 
that there should be more. Most of the alternatives have been relatively neglected by most 
mainstream investigators and by peer-reviewed funding, despite the fact that some of them could 
be relatively cheaply tested. This has three unfortunate consequences: 1) dogma (both 
establishment and anti-establishment) fills the void left by absence of data, 2) potentially useful 
treatments are rejected or neglected without a fair trial by clinicians who demand scientific 
validation, and 3) possibly ineffective or even dangerous treatments can be advocated without the 
data necessary to debunk them. This area needs more scientific attention. 
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